MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28347-28376

  Mathe, Andrea ^a,b   Scott, Rodney J ^a,b,c   Avery Kiejda, Kelly A ^a,b  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

DNA methylation; MicroRNA; Triple negative breast cancer

Indexed keywords

ESTROGEN; GAMMA UROGASTRONE; MICRORNA 155; MICRORNA 16; MICRORNA 21; MICRORNA 222; MICRORNA 223; PROGESTERONE; BIOLOGICAL MARKER; MICRORNA;

CANCER PATIENT; CPG ISLAND; DNA METHYLATION; EPIGENETIC REPRESSION; EPITHELIAL MESENCHYMAL TRANSITION; GENE INACTIVATION; GENETIC HETEROGENEITY; IMMUNOSUPPRESSIVE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; EPISTASIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METASTASIS; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; BIOMARKERS; DNA METHYLATION; EPIGENESIS, GENETIC; EPISTASIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM METASTASIS; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84949058191     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226090     Document Type: Review

References (257)

1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer 2015, 136, E359-E386. [CrossRef] [PubMed]
2. Den Hollander, P.; Savage, M.I.; Brown, P.H. Targeted therapy for breast cancer prevention. Front. Oncol. 2013, 3. [CrossRef] [PubMed]
3. Maxmen, A. The hard facts. Nature 2012, 485, S50-S51. [CrossRef] [PubMed]
4. Gucalp, A.; Traina, T.A. Triple-negative breast cancer: Adjuvant therapeutic options. Chemother. Res. Pract. 2011, 2011. [CrossRef] [PubMed]
5. Wong-Brown, M.W.; Meldrum, C.J.; Carpenter, J.E.; Clarke, C.L.; Narod, S.A.; Jakubowska, A.; Rudnicka, H.; Lubinski, J.; Scott, R.J. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res. Treat. 2015, 150, 71-80. [CrossRef] [PubMed]
6. Carey, L.; Winer, E.; Viale, G.; Cameron, D.; Gianni, L. Triple-negative breast cancer: Disease entity or title of convenience? Nat. Rev. Clin. Oncol. 2010, 7, 683-692. [CrossRef] [PubMed]
7. Arnedos, M.; Bihan, C.; Delaloge, S.; Andre, F. Triple-negative breast cancer: Are we making headway at least? Ther. Adv. Med. Oncol. 2012, 4, 195-210. [CrossRef] [PubMed]
8. Sorlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874. [CrossRef] [PubMed]
9. Bae, S.Y.; Lee, S.K.; Koo, M.Y.; Hur, S.M.; Choi, M.Y.; Cho, D.H.; Kim, S.; Choe, J.H.; Lee, J.E.; Kim, J.H.; et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res. Treat. 2011, 126, 471-478. [CrossRef] [PubMed]
10. Jung, S.Y.; Kim, H.Y.; Nam, B.H.; Min, S.Y.; Lee, S.J.; Park, C.; Kwon, Y.; Kim, E.A.; Ko, K.L.; Shin, K.H.; et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res. Treat. 2010, 120, 627-637. [CrossRef] [PubMed]
11. Honma, N.; Saji, S.; Kurabayashi, R.I.E.; Aida, J.; Arai, T.; Horii, R.I.E.; Akiyama, F.; Iwase, T.; Harada, N.; Younes, M.; et al. Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast. APMIS 2008, 116, 923-930. [CrossRef] [PubMed]
12. Reis-Filho, J.S.; Tutt, A.N. Triple negative tumours: A critical review. Histopathology 2008, 52, 108-118. [CrossRef] [PubMed]
13. Bauer, K.R.; Brown, M.; Cress, R.D.; Parise, C.A.; Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the california cancer registry. Cancer 2007, 109, 1721-1728. [CrossRef] [PubMed]
14. Dent, R.; Hanna, W.M.; Trudeau, M.; Rawlinson, E.; Sun, P.; Narod, S.A. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 2009, 115, 423-428. [CrossRef] [PubMed]
15. Parvin, F.; Peddi, M.J.E.; Cynthia, M. Molecular basis of triple negative breast cancer and implications for therapy. Int. J. Breast Cancer 2012, 2012. [CrossRef]
16. Anders, C.K.; Winer, E.P.; Ford, J.M.; Dent, R.; Silver, D.P.; Sledge, G.W.; Carey, L.A. Poly(adp-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer. Clin. Cancer Res. 2010, 16, 4702-4710. [CrossRef] [PubMed]
17. O'Shaughnessy, J.; Osborne, C.; Pippen, J.E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I.C.; Sherman, B.M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364, 205-214. [CrossRef] [PubMed]
18. O'Shaughnessy, J.; Schwartzberg, L.; Danso, M.A.; Miller, K.D.; Rugo, H.S.; Neubauer, M.; Robert, N.; Hellerstedt, B.; Saleh, M.; Richards, P.; et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 2014, 32, 3840-3847. [CrossRef] [PubMed]
19. Linderholm, B.K.; Hellborg, H.; Johansson, U.; Elmberger, G.; Skoog, L.; Lehtio, J.; Lewensohn, R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 2009, 20, 1639-1646. [CrossRef] [PubMed]
20. O'Shaughnessy, J.; Dieras, V.; Glaspy, J.; Brufsky, A.; Miller, K.; Miles, D.; Koralewski, P.; Phan, S.; Bhattacharya, S. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res. 2009, 69. [CrossRef]
21. Nielsen, T.O.; Hsu, F.D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10, 5367-5374. [CrossRef] [PubMed]
22. Baselga, J.; Gomez, P.; Greil, R.; Braga, S.; Climent, M.A.;Wardley, A.M.; Kaufman, B.; Stemmer, S.M.; Pego, A.; Chan, A.; et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 2013, 31, 2586-2592. [CrossRef] [PubMed]
23. Hiscox, S.; Morgan, L.; Green, T.P.; Barrow, D.; Gee, J.; Nicholson, R.I. Elevated SRC activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 2006, 97, 263-274. [CrossRef] [PubMed]
24. Finn, R.S. Targeting src in breast cancer. Ann. Oncol. 2008, 19, 1379-1386. [CrossRef] [PubMed]
25. Fornier, M.N.; Morris, P.G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A.D.; et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann. Oncol. 2011, 22, 2575-2581. [CrossRef] [PubMed]
26. Shah, P.D.; Gucalp, A.; Traina, T.A. The role of the androgen receptor in triple-negative breast cancer. Womens Health 2013, 9, 351-360. [CrossRef] [PubMed]
27. Anestis, A.; Karamouzis, M.V.; Dalagiorgou, G.; Papavassiliou, A.G. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat. Rev. 2015, 41, 547-553. [CrossRef] [PubMed]
28. Gucalp, A.; Tolaney, S.; Isakoff, S.J.; Ingle, J.N.; Liu, M.C.; Carey, L.A.; Blackwell, K.; Rugo, H.; Nabell, L.; Forero, A.; et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin. Cancer Res. 2013, 19, 5505-5512. [CrossRef] [PubMed]
29. Petrelli, F.; Coinu, A.; Borgonovo, K.; Cabiddu, M.; Ghilardi, M.; Lonati, V.; Barni, S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2014, 144, 223-232. [CrossRef] [PubMed]
30. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752. [CrossRef] [PubMed]
31. Eroles, P.; Bosch, A.; Alejandro Pérez-Fidalgo, J.; Lluch, A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 2011, 38, 698-707. [CrossRef] [PubMed]
32. Prat, A.; Perou, C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011, 5, 5-23. [CrossRef] [PubMed]
33. Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486, 346-352. [PubMed]
34. Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011, 121, 2750-2767. [CrossRef] [PubMed]
35. Burstein, M.D.; Tsimelzon, A.; Poage, G.M.; Covington, K.R.; Contreras, A.; Fuqua, S.A.; Savage, M.I.; Osborne, C.K.; Hilsenbeck, S.G.; Chang, J.C.; et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 2015, 21, 1688-1698. [CrossRef] [PubMed]
36. Prat, A.; Lluch, A.; Albanell, J.; Barry,W.T.; Fan, C.; Chacon, J.I.; Parker, J.S.; Calvo, L.; Plazaola, A.; Arcusa, A.; et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br. J. Cancer 2014, 111, 1532-1541. [CrossRef] [PubMed]
37. Campone, M.; Valo, I.; Jezequel, P.; Moreau, M.; Boissard, A.; Campion, L.; Loussouarn, D.; Verriele, V.; Coqueret, O.; Guette, C. Prediction of recurrence and survival for triple-negative breast cancer by a protein signature in tissue samples. Mol. Cell. Proteom. 2015, 14, 2936-2946. [CrossRef] [PubMed]
38. Shen, S.; Sun, Q.; Liang, Z.; Cui, X.; Ren, X.; Chen, H.; Zhang, X.; Zhou, Y. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS ONE 2014, 9, e100664. [CrossRef] [PubMed]
39. Atkinson, R.L.; Yang,W.T.; Rosen, D.G.; Landis, M.D.; Wong, H.; Lewis, M.T.; Creighton, C.J.; Sexton, K.R.; Hilsenbeck, S.G.; Sahin, A.A.; et al. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res. 2013, 15. [CrossRef] [PubMed]
40. Braakhuis, B.J.; Leemans, C.R.; Brakenhoff, R.H. Using tissue adjacent to carcinoma as a normal control: An obvious but questionable practice. J. Pathol. 2004, 203, 620-621. [CrossRef] [PubMed]
41. Waddington, C.H. The epigenotype. Endeavour 1942, 1, 18-20. [CrossRef] [PubMed]
42. Holliday, R. The inheritance of epigenetic defects. Science 1987, 238, 163-170. [CrossRef] [PubMed]
43. Virani, S.; Colacino, J.A.; Kim, J.H.; Rozek, L.S. Cancer epigenetics: A brief review. ILAR J. 2012, 53, 359-369. [CrossRef] [PubMed]
44. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854. [CrossRef]
45. Beezhold, K.J.; Castranova, V.; Chen, F. Microprocessor of microRNAs: Regulation and potential for therapeutic intervention. Mol. Cancer 2010, 9. [CrossRef] [PubMed]
46. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866. [CrossRef] [PubMed]
47. O'Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10, 111-122. [CrossRef] [PubMed]
48. Kozomara, A.; Griffiths-Jones, S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014, 42, D68-D73. [CrossRef] [PubMed]
49. Andorfer, C.A.; Necela, B.M.; Thompson, E.A.; Perez, E.A. MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med. 2011, 17, 313-319. [CrossRef] [PubMed]
50. Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92-105. [CrossRef] [PubMed]
51. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509-524. [CrossRef] [PubMed]
52. O'Day, E.; Lal, A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010, 12. [CrossRef] [PubMed]
53. Ying, S.Y.; Chang, D.C.; Lin, S.L. The microRNA (miRNA): Overview of the RNA genes that modulate gene function. Mol. Biotechnol. 2008, 38, 257-268. [CrossRef] [PubMed]
54. Winter, J.; Diederichs, S. MicroRNA biogenesis and cancer. Methods Mol. Biol. 2011, 676, 3-22. [PubMed]
55. McDaneld, T.G. MicroRNA: Mechanism of gene regulation and application to livestock. J. Anim. Sci. 2009, 87, E21-E28. [CrossRef] [PubMed]
56. Rusk, N. When microRNAs activate translation. Nat. Methods 2008, 5, 122-123. [CrossRef]
57. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524-15529. [CrossRef] [PubMed]
58. Voorhoeve, P.M. MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim. Biophys. Acta 2010, 1805, 72-86. [CrossRef] [PubMed]
59. Izumiya, M.; Tsuchiya, N.; Okamoto, K.; Nakagama, H. Systematic exploration of cancer-associated microRNA through functional screening assays. Cancer Sci. 2011, 102, 1615-1621. [CrossRef] [PubMed]
60. Baffa, R.; Fassan, M.; Volinia, S.; O'Hara, B.; Liu, C.G.; Palazzo, J.P.; Gardiman, M.; Rugge, M.; Gomella, L.G.; Croce, C.M.; et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 2009, 219, 214-221. [CrossRef] [PubMed]
61. Di Leva, G.; Briskin, D.; Croce, C.M. MicroRNA in cancer: New hopes for antineoplastic chemotherapy. Ups. J. Med. Sci. 2012, 117, 202-216. [CrossRef] [PubMed]
62. Heneghan, H.M.; Miller, N.; Lowery, A.J.; Sweeney, K.J.; Kerin, M.J. MicroRNAs as novel biomarkers for breast cancer. J. Oncol. 2009, 2009. [CrossRef] [PubMed]
63. Jeffrey, S.S. Cancer biomarker profiling with microRNAs. Nat. Biotechnol. 2008, 26, 400-401. [CrossRef] [PubMed]
64. Avery-Kiejda, K.A.; Braye, S.G.; Mathe, A.; Forbes, J.F.; Scott, R.J. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer 2014, 14. [CrossRef] [PubMed]
65. Cascione, L.; Gasparini, P.; Lovat, F.; Carasi, S.; Pulvirenti, A.; Ferro, A.; Alder, H.; He, G.; Vecchione, A.; Croce, C.M.; et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS ONE 2013, 8, e55910. [CrossRef] [PubMed]
66. Aydogdu, E.; Katchy, A.; Tsouko, E.; Lin, C.Y.; Haldosen, L.A.; Helguero, L.; Williams, C. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 2012, 33, 1502-1511. [CrossRef] [PubMed]
67. Gregory, P.A.; Bracken, C.P.; Bert, A.G.; Goodall, G.J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7, 3112-3118. [CrossRef] [PubMed]
68. Howe, E.N.; Cochrane, D.R.; Richer, J.K. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011, 13. [CrossRef] [PubMed]
69. Ren, Y.; Han, X.; Yu, K.; Sun, S.; Zhen, L.; Li, Z.; Wang, S. MicroRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. Mol. Med. Rep. 2014, 10, 315-321. [CrossRef] [PubMed]
70. Lowery, A.J.; Miller, N.; Devaney, A.; McNeill, R.E.; Davoren, P.A.; Lemetre, C.; Benes, V.; Schmidt, S.; Blake, J.; Ball, G.; et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11. [CrossRef] [PubMed]
71. Janssen, E.A.; Slewa, A.; Gudlaugsson, E.; Jonsdottir, K.; Skaland, I.; Soiland, H.; Baak, J.P. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod. Pathol. 2010, 23, 1567-1576. [CrossRef] [PubMed]
72. Sempere, L.F.; Christensen, M.; Silahtaroglu, A.; Bak, M.; Heath, C.V.; Schwartz, G.; Wells, W.; Kauppinen, S.; Cole, C.N. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67, 11612-11620. [CrossRef] [PubMed]
73. De Rinaldis, E.; Gazinska, P.; Mera, A.; Modrusan, Z.; Fedorowicz, G.M.; Burford, B.; Gillett, C.; Marra, P.; Grigoriadis, A.; Dornan, D.; et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genom. 2013, 14. [CrossRef] [PubMed]
74. Kolacinska, A.; Morawiec, J.; Pawlowska, Z.; Szemraj, J.; Szymanska, B.; Malachowska, B.; Morawiec, Z.; Morawiec-Sztandera, A.; Pakula, L.; Kubiak, R.; et al. Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients. DNA Cell Biol. 2014, 33, 624-629. [CrossRef] [PubMed]
75. Berber, U.; Yilmaz, I.; Narli, G.; Haholu, A.; Kucukodaci, Z.; Demirel, D. miR-205 and miR-200c: Predictive micro RNAs for lymph node metastasis in triple negative breast cancer. J. Breast Cancer 2014, 17, 143-148. [CrossRef] [PubMed]
76. Chen,W.; Cai, F.; Zhang, B.; Barekati, Z.; Zhong, X.Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: Potential biomarkers. Tumour Biol. 2013, 34, 455-462. [CrossRef] [PubMed]
77. Piovan, C.; Palmieri, D.; di Leva, G.; Braccioli, L.; Casalini, P.; Nuovo, G.; Tortoreto, M.; Sasso, M.; Plantamura, I.; Triulzi, T.; et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol. Oncol. 2012, 6, 458-472. [CrossRef] [PubMed]
78. Wang, C.; Zheng, X.; Shen, C.; Shi, Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J. Exp. Clin. Cancer Res. 2012, 31. [CrossRef] [PubMed]
79. Koerner, C.; Keklikoglou, I.; Bender, C.;Woerner, A.; Muenstermann, E.;Wiemann, S. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J. Biol. Chem. 2013, 288, 8750-8761. [CrossRef] [PubMed]
80. Sossey-Alaoui, K.; Downs-Kelly, E.; Das, M.; Izem, L.; Tubbs, R.; Plow, E.F. Wave3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int. J. Cancer 2011, 129, 1331-1343. [CrossRef] [PubMed]
81. Mackiewicz, M.; Huppi, K.; Pitt, J.J.; Dorsey, T.H.; Ambs, S.; Caplen, N.J. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res. Treat. 2011, 130, 663-679. [CrossRef] [PubMed]
82. Bisso, A.; Faleschini, M.; Zampa, F.; Capaci, V.; de Santa, J.; Santarpia, L.; Piazza, S.; Cappelletti, V.; Daidone, M.; Agami, R.; et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013, 12, 1679-1687. [CrossRef] [PubMed]
83. Taylor, M.A.; Sossey-Alaoui, K.; Thompson, C.L.; Danielpour, D.; Schiemann, W.P. TGF-β upregulates mir-181a expression to promote breast cancer metastasis. J. Clin. Investig. 2013, 123, 150-163. [CrossRef] [PubMed]
84. Garcia, A.I.; Buisson, M.; Bertrand, P.; Rimokh, R.; Rouleau, E.; Lopez, B.S.; Lidereau, R.; Mikaelian, I.; Mazoyer, S. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med. 2011, 3, 279-290. [CrossRef] [PubMed]
85. Liu, H.;Wang, Y.; Li, X.; Zhang, Y.-J.; Li, J.; Zheng, Y.-Q.; Liu, M.; Song, X.; Li, X.-R. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1. Tumor Biol. 2013, 34, 1713-1722. [CrossRef] [PubMed]
86. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9, 582-589. [CrossRef] [PubMed]
87. Chen, J.; Tian, W.; Cai, H.; He, H.; Deng, Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med. Oncol. 2012, 29, 2527-2534. [CrossRef] [PubMed]
88. Korpal, M.; Lee, E.S.; Hu, G.; Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283, 14910-14914. [CrossRef] [PubMed]
89. Lin, J.; Liu, C.; Gao, F.; Mitchel, R.E.; Zhao, L.; Yang, Y.; Lei, J.; Cai, J. miR-200c enhances radiosensitivity of human breast cancer cells. J. Cell. Biochem. 2013, 114, 606-615. [CrossRef] [PubMed]
90. Boyerinas, B.; Park, S.M.; Hau, A.; Murmann, A.E.; Peter, M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17, F19-F36. [CrossRef] [PubMed]
91. Bussing, I.; Slack, F.J.; Grosshans, H. Let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 2008, 14, 400-409. [CrossRef] [PubMed]
92. Liu, X.; Gu, X.; Sun, L.; Flowers, A.B.; Rademaker, A.W.; Zhou, Y.; Kiyokawa, H. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: Involvement of the RB-microRNA axis. BMC Cancer 2014, 14. [CrossRef] [PubMed]
93. Nassirpour, R.; Mehta, P.P.; Baxi, S.M.; Yin, M.J. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE 2013, 8, e62170. [CrossRef] [PubMed]
94. Augoff, K.; McCue, B.; Plow, E.F.; Sossey-Alaoui, K. miR-31 and its host gene LncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol. Cancer 2012, 11. [CrossRef] [PubMed]
95. Humphries, B.;Wang, Z.; Oom, A.L.; Fisher, T.; Tan, D.; Cui, Y.; Jiang, Y.; Yang, C. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis 2014, 35, 2254-2263. [CrossRef] [PubMed]
96. Gan, R.; Yang, Y.; Yang, X.; Zhao, L.; Lu, J.; Meng, Q.H. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 2014, 21, 290-296. [CrossRef] [PubMed]
97. Rao, X.; di Leva, G.; Li, M.; Fang, F.; Devlin, C.; Hartman-Frey, C.; Burow, M.E.; Ivan, M.; Croce, C.M.; Nephew, K.P. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30, 1082-1097. [CrossRef] [PubMed]
98. Xiong, J.; Yu, D.; Wei, N.; Fu, H.; Cai, T.; Huang, Y.; Wu, C.; Zheng, X.; Du, Q.; Lin, D.; et al. An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J. 2010, 277, 1684-1694. [CrossRef] [PubMed]
99. Yoshimoto, N.; Toyama, T.; Takahashi, S.; Sugiura, H.; Endo, Y.; Iwasa, M.; Fujii, Y.; Yamashita, H. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res. Treat. 2011, 130, 331-339. [CrossRef] [PubMed]
100. Fang, C.; Zhao, Y.; Guo, B. MiR-199b-5p targets HER2 in breast cancer cells. J. Cell. Biochem. 2013, 114, 1457-1463. [CrossRef] [PubMed]
101. Leivonen, S.K.; Sahlberg, K.K.; Makela, R.; Due, E.U.; Kallioniemi, O.; Borresen-Dale, A.L.; Perala, M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol. Oncol. 2014, 8, 93-104. [CrossRef] [PubMed]
102. Scott, G.K.; Goga, A.; Bhaumik, D.; Berger, C.E.; Sullivan, C.S.; Benz, C.C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 2007, 282, 1479-1486. [CrossRef] [PubMed]
103. Ell, B.; Qiu, Q.; Wei, Y.; Mercatali, L.; Ibrahim, T.; Amadori, D.; Kang, Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. J. Biol. Chem. 2014, 289, 21888-21895. [CrossRef] [PubMed]
104. Radojicic, J.; Zaravinos, A.; Vrekoussis, T.; Kafousi, M.; Spandidos, D.A.; Stathopoulos, E.N. MicroRNA expression analysis in triple-negative (ER, PR and HER2/neu) breast cancer. Cell Cycle 2011, 10, 507-517. [CrossRef] [PubMed]
105. Chang, S.; Wang, R.H.; Akagi, K.; Kim, K.A.; Martin, B.K.; Cavallone, L.; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Haines, D.C.; Basik, M.; Mai, P.; et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat. Med. 2011, 17, 1275-1282. [CrossRef] [PubMed]
106. Foekens, J.A.; Sieuwerts, A.M.; Smid, M.; Look, M.P.; de Weerd, V.; Boersma, A.W.; Klijn, J.G.; Wiemer, E.A.; Martens, J.W. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl. Acad. Sci. USA 2008, 105, 13021-13026. [CrossRef] [PubMed]
107. Toyama, T.; Kondo, N.; Endo, Y.; Sugiura, H.; Yoshimoto, N.; Iwasa, M.; Takahashi, S.; Fujii, Y.; Yamashita, H. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn. J. Clin. Oncol. 2012, 42, 256-263. [CrossRef] [PubMed]
108. Svoboda, M.; Sana, J.; Redova, M.; Navratil, J.; Palacova, M.; Fabian, P.; Slaby, O.; Vyzula, R. mir-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn. Pathol. 2012, 7. [CrossRef] [PubMed]
109. Yamakuchi, M.; Lowenstein, C.J. miR-34, SIRT1 and p53: The feedback loop. Cell Cycle 2009, 8, 712-715. [CrossRef] [PubMed]
110. Buffa, F.M.; Camps, C.;Winchester, L.; Snell, C.E.; Gee, H.E.; Sheldon, H.; Taylor, M.; Harris, A.L.; Ragoussis, J. MicroRNA-associated progression pathways and potential therapeutic targets identified by integrated mrna and microRNA expression profiling in breast cancer. Cancer Res. 2011, 71, 5635-5645. [CrossRef] [PubMed]
111. Dong, G.; Liang, X.; Wang, D.; Gao, H.; Wang, L.; Wang, L.; Liu, J.; Du, Z. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med. Oncol. 2014, 31. [CrossRef] [PubMed]
112. MacKenzie, T.A.; Schwartz, G.N.; Calderone, H.M.; Graveel, C.R.; Winn, M.E.; Hostetter, G.; Wells, W.A.; Sempere, L.F. Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am. J. Pathol. 2014, 184, 3217-3225. [CrossRef] [PubMed]
113. Kong,W.; He, L.; Richards, E.J.; Challa, S.; Xu, C.X.; Permuth-Wey, J.; Lancaster, J.M.; Coppola, D.; Sellers, T.A.; Djeu, J.Y.; et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014, 33, 679-689. [CrossRef] [PubMed]
114. Kolacinska, A.; Morawiec, J.; Fendler, W.; Malachowska, B.; Morawiec, Z.; Szemraj, J.; Pawlowska, Z.; Chowdhury, D.; Choi, Y.E.; Kubiak, R.; et al. Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: Preliminary report. Mol. Biol. Rep. 2014, 41, 2851-2857. [CrossRef] [PubMed]
115. Ouyang, M.; Li, Y.; Ye, S.; Ma, J.; Lu, L.; Lv, W.; Chang, G.; Li, X.; Li, Q.; Wang, S.; et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS ONE 2014, 9, e96228. [CrossRef] [PubMed]
116. Gasparini, P.; Cascione, L.; Fassan, M.; Lovat, F.; Guler, G.; Balci, S.; Irkkan, C.; Morrison, C.; Croce, C.M.; Shapiro, C.L.; et al. MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 2014, 5, 1174-1184. [CrossRef] [PubMed]
117. Ma, L.; Reinhardt, F.; Pan, E.; Soutschek, J.; Bhat, B.; Marcusson, E.G.; Teruya-Feldstein, J.; Bell, G.W.; Weinberg, R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28, 341-347. [CrossRef] [PubMed]
118. Ma, L.; Teruya-Feldstein, J.;Weinberg, R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449, 682-688. [CrossRef]
119. Parrella, P.; Barbano, R.; Pasculli, B.; Fontana, A.; Copetti, M.; Valori, V.M.; Poeta, M.L.; Perrone, G.; Righi, D.; Castelvetere, M.; et al. Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol. Cancer 2014, 13. [CrossRef] [PubMed]
120. Liu, Y.; Cai, Q.; Bao, P.P.; Su, Y.; Cai, H.; Wu, J.; Ye, F.; Guo, X.; Zheng, W.; Zheng, Y.; et al. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. Breast Cancer Res. Treat. 2015, 152, 183-191. [CrossRef] [PubMed]
121. Kong, D.; Li, Y.; Wang, Z.; Sarkar, F. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers 2011, 3, 716-729. [CrossRef] [PubMed]
122. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420-1428. [CrossRef] [PubMed]
123. 3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. BCR 2006, 8. [CrossRef] [PubMed]
124. Watanabe, S.; Ueda, Y.; Akaboshi, S.; Hino, Y.; Sekita, Y.; Nakao, M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 2009, 174, 854-868. [CrossRef] [PubMed]
125. Taki, M.; Verschueren, K.; Yokoyama, K.; Nagayama, M.; Kamata, N. Involvement of ETS-1 transcription factor in inducing matrix metalloproteinase-2 expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Int. J. Oncol. 2006, 28, 487-496. [CrossRef] [PubMed]
126. Mamuya, F.A.; Duncan, M.K. aV integrins and TGF-β-induced EMT: A circle of regulation. J. Cell. Mol. Med. 2012, 16, 445-455. [CrossRef] [PubMed]
127. Borok, Z. Role for α3 integrin in EMT and pulmonary fibrosis. J. Clin. Investig. 2009, 119, 7-10. [CrossRef] [PubMed]
128. Van der Velden, J.L.; Guala, A.S.; Leggett, S.E.; Sluimer, J.; Badura, E.C.; Janssen-Heininger, Y.M. Induction of a mesenchymal expression program in lung epithelial cells by Wnt/β-catenin requires the presence of c-Jun N-terminal kinase 1. Am. J. Respir. Cell Mol. Biol. 2012, 47, 306-314. [CrossRef] [PubMed]
129. Bao, B.; Wang, Z.; Ali, S.; Kong, D.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A.S.; Miele, L.; Sarkar, F.H. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307, 26-36. [CrossRef] [PubMed]
130. Ahmad, A.; Sarkar, S.H.; Bitar, B.; Ali, S.; Aboukameel, A.; Sethi, S.; Li, Y.; Bao, B.; Kong, D.; Banerjee, S.; et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo leading to anticancer activity against breast cancer cells. Mol. Cancer Ther. 2012, 11, 2193-2201. [CrossRef] [PubMed]
131. Cao, M.; Seike, M.; Soeno, C.; Mizutani, H.; Kitamura, K.; Minegishi, Y.; Noro, R.; Yoshimura, A.; Cai, L.; Gemma, A. MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int. J. Oncol. 2012, 41, 869-875. [PubMed]
132. Ceppi, P.; Mudduluru, G.; Kumarswamy, R.; Rapa, I.; Scagliotti, G.V.; Papotti, M.; Allgayer, H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res. 2010, 8, 1207-1216. [CrossRef] [PubMed]
133. Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.;Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2012. [CrossRef] [PubMed]
134. Han, M.; Liu, M.; Wang, Y.; Chen, X.; Xu, J.; Sun, Y.; Zhao, L.; Qu, H.; Fan, Y.; Wu, C. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting pten. PLoS ONE 2012, 7, e39520. [CrossRef] [PubMed]
135. Howe, E.N.; Cochrane, D.R.; Richer, J.K. The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity. J. Mammary Gland Biol. Neoplasia 2012, 17, 65-77. [CrossRef] [PubMed]
136. Hur, K.; Toiyama, Y.; Takahashi, M.; Balaguer, F.; Nagasaka, T.; Koike, J.; Hemmi, H.; Koi, M.; Boland, C.R.; Goel, A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013, 62, 1315-1326. [CrossRef] [PubMed]
137. Sarrio, D.; Rodriguez-Pinilla, S.M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68, 989-997. [CrossRef] [PubMed]
138. Castilla, M.A.; Diaz-Martin, J.; Sarrio, D.; Romero-Perez, L.; Lopez-Garcia, M.A.; Vieites, B.; Biscuola, M.; Ramiro-Fuentes, S.; Isacke, C.M.; Palacios, J. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS ONE 2012, 7, e47709. [CrossRef] [PubMed]
139. Volinia, S.; Galasso, M.; Sana, M.E.; Wise, T.F.; Palatini, J.; Huebner, K.; Croce, C.M. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. USA 2012, 109, 3024-3029. [CrossRef] [PubMed]
140. Dykxhoorn, D.M.; Wu, Y.; Xie, H.; Yu, F.; Lal, A.; Petrocca, F.; Martinvalet, D.; Song, E.; Lim, B.; Lieberman, J. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 2009, 4, e7181. [CrossRef] [PubMed]
141. Korpal, M.; Ell, B.J.; Buffa, F.M.; Ibrahim, T.; Blanco, M.A.; Celia-Terrassa, T.; Mercatali, L.; Khan, Z.; Goodarzi, H.; Hua, Y.; et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17, 1101-1108. [CrossRef] [PubMed]
142. Gregory, P.A.; Bracken, C.P.; Smith, E.; Bert, A.G.;Wright, J.A.; Roslan, S.; Morris, M.;Wyatt, L.; Farshid, G.; Lim, Y.Y.; et al. An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 2011, 22, 1686-1698. [CrossRef] [PubMed]
143. Howe, E.N.; Cochrane, D.R.; Cittelly, D.M.; Richer, J.K. MiR-200c targets a NF-κB up-regulated Trkb/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS ONE 2012, 7, e49987. [CrossRef] [PubMed]
144. Baulida, J.; Garcia de Herreros, A. Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy. Biochim. Biophys. Acta 2015, 1856, 55-61. [CrossRef] [PubMed]
145. Fang, J.H.; Zhou, H.C.; Zhang, C.; Shang, L.R.; Zhang, L.; Xu, J.; Zheng, L.; Yuan, Y.; Guo, R.P.; Jia, W.H.; et al. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology 2015, 62, 452-465. [CrossRef] [PubMed]
146. Gao, J.; Zhu, Y.; Nilsson, M.; Sundfeldt, K. TGF-β isoforms induce emt independent migration of ovarian cancer cells. Cancer Cell Int. 2014, 14. [CrossRef] [PubMed]
147. Zhang, P.; Sun, Y.; Ma, L. ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 2015, 14, 481-487. [CrossRef] [PubMed]
148. Han, M.; Wang, Y.; Liu, M.; Bi, X.; Bao, J.; Zeng, N.; Zhu, Z.; Mo, Z.; Wu, C.; Chen, X. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012, 103, 1058-1064. [CrossRef] [PubMed]
149. Huang, T.H.;Wu, F.; Loeb, G.B.; Hsu, R.; Heidersbach, A.; Brincat, A.; Horiuchi, D.; Lebbink, R.J.; Mo, Y.Y.; Goga, A.; et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J. Biol.Chem. 2009, 284, 18515-18524. [CrossRef] [PubMed]
150. Yan, L.X.; Huang, X.F.; Shao, Q.; Huang, M.Y.; Deng, L.;Wu, Q.L.; Zeng, Y.X.; Shao, J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14, 2348-2360. [CrossRef] [PubMed]
151. Jiang, H.; Zhang, G.; Wu, J.H.; Jiang, C.P. Diverse roles of miR-29 in cancer (review). Oncol. Rep. 2014, 31, 1509-1516. [CrossRef] [PubMed]
152. Rostas, J.W., 3rd; Pruitt, H.C.; Metge, B.J.; Mitra, A.; Bailey, S.K.; Bae, S.; Singh, K.P.; Devine, D.J.; Dyess, D.L.; Richards,W.O.; et al. MicroRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol. Cancer 2014, 13. [CrossRef] [PubMed]
153. Han, X.; Yan, S.; Weijie, Z.; Feng, W.; Liuxing, W.; Mengquan, L.; Qingxia, F. Critical role of miR-10b in transforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer. Cancer Gene Ther. 2014, 21, 60-67. [CrossRef] [PubMed]
154. Minard, M.E.; Ellis, L.M.; Gallick, G.E. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin. Exp. Metastasis 2006, 23, 301-313. [CrossRef] [PubMed]
155. Gwak, J.M.; Kim, H.J.; Kim, E.J.; Chung, Y.R.; Yun, S.; Seo, A.N.; Lee, H.J.; Park, S.Y. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res. Treat. 2014, 147, 39-49. [CrossRef] [PubMed]
156. Ma, L.; Young, J.; Prabhala, H.; Pan, E.; Mestdagh, P.; Muth, D.; Teruya-Feldstein, J.; Reinhardt, F.; Onder, T.T.; Valastyan, S.; et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010, 12, 247-256. [CrossRef] [PubMed]
157. Adams, B.D.; Furneaux, H.; White, B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 2007, 21, 1132-1147. [CrossRef] [PubMed]
158. Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065-7070. [CrossRef] [PubMed]
159. Kondo, N.; Toyama, T.; Sugiura, H.; Fujii, Y.; Yamashita, H. miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res. 2008, 68, 5004-5008. [CrossRef] [PubMed]
160. Guttilla, I.K.; Phoenix, K.N.; Hong, X.; Tirnauer, J.S.; Claffey, K.P.; White, B.A. Prolonged mammosphere culture of MCF-7 cells induces an emt and repression of the estrogen receptor by microRNAs. Breast Cancer Res. Treat. 2012, 132, 75-85. [CrossRef] [PubMed]
161. Zhao, J.J.; Lin, J.; Yang, H.; Kong, W.; He, L.; Ma, X.; Coppola, D.; Cheng, J.Q. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283, 31079-31086. [CrossRef] [PubMed]
162. Cao, M.; Nie, W.; Li, J.; Zhang, Y.; Yan, X.; Guan, X.; Chen, X.; Zen, K.; Zhang, C.Y.; Jiang, X.; et al. MicroRNA-495 induces breast cancer cell migration by targeting JAM-A. Protein Cell 2014, 5, 862-872. [CrossRef] [PubMed]
163. Hwang-Verslues,W.W.; Chang, P.H.; Wei, P.C.; Yang, C.Y.; Huang, C.K.; Kuo,W.H.; Shew, J.Y.; Chang, K.J.; Lee, E.Y.; Lee,W.H. MiR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and redd1. Oncogene 2011, 30, 2463-2474. [CrossRef] [PubMed]
164. Neel, J.C.; Lebrun, J.J. Activin and TGFβ regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Cell Signal. 2013, 25, 1556-1566. [CrossRef] [PubMed]
165. Castellano, L.; Giamas, G.; Jacob, J.; Coombes, R.C.; Lucchesi, W.; Thiruchelvam, P.; Barton, G.; Jiao, L.R.; Wait, R.; Waxman, J.; et al. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proc. Natl. Acad. Sci. USA 2009, 106, 15732-15737. [CrossRef] [PubMed]
166. Yu, Z.;Wang, C.;Wang, M.; Li, Z.; Casimiro, M.C.; Liu, M.;Wu, K.; Whittle, J.; Ju, X.; Hyslop, T.; et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J. Cell Biol. 2008, 182, 509-517. [CrossRef] [PubMed]
167. Acunzo, M.; Visone, R.; Romano, G.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Condorelli, G.; et al. miR-130a targets met and induces trail-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012, 31, 634-642. [CrossRef] [PubMed]
168. Gotte, M.; Mohr, C.; Koo, C.Y.; Stock, C.; Vaske, A.K.; Viola, M.; Ibrahim, S.A.; Peddibhotla, S.; Teng, Y.H.; Low, J.Y.; et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010, 29, 6569-6580. [CrossRef] [PubMed]
169. Sachdeva, M.; Mo, Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010, 70, 378-387. [CrossRef] [PubMed]
170. Spizzo, R.; Nicoloso, M.S.; Lupini, L.; Lu, Y.; Fogarty, J.; Rossi, S.; Zagatti, B.; Fabbri, M.; Veronese, A.; Liu, X.; et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death Differ. 2010, 17, 246-254. [CrossRef] [PubMed]
171. Zhang, H.; Cai, K.; Wang, J.; Wang, X.; Cheng, K.; Shi, F.; Jiang, L.; Zhang, Y.; Dou, J. MiR-7, inhibited indirectly by lincrna hotair, directly inhibits SETDB1 and reverses the emt of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells 2014, 32, 2858-2868. [CrossRef] [PubMed]
172. Hong, S.; Noh, H.; Teng, Y.; Shao, J.; Rehmani, H.; Ding, H.F.; Dong, Z.; Su, S.B.; Shi, H.; Kim, J.; et al. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia 2014, 16, 279-290. [CrossRef] [PubMed]
173. Parker, J.S.; Mullins, M.; Cheang, M.C.U.; Leung, S.; Voduc, D.; Vickery, T.; Davies, S.; Fauron, C.; He, X.; Hu, Z.; et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27, 1160-1167. [CrossRef] [PubMed]
174. Cortez, M.A.;Welsh, J.W.; Calin, G.A. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012, 195, 151-161. [PubMed]
175. Roth, C.; Rack, B.; Muller, V.; Janni,W.; Pantel, K.; Schwarzenbach, H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. BCR 2010, 12. [CrossRef] [PubMed]
176. Sochor, M.; Basova, P.; Pesta, M.; Dusilkova, N.; Bartos, J.; Burda, P.; Pospisil, V.; Stopka, T. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 2014, 14. [CrossRef] [PubMed]
177. Wang, F.; Zheng, Z.; Guo, J.; Ding, X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 2010, 119, 586-593. [CrossRef] [PubMed]
178. Eichelser, C.; Flesch-Janys, D.; Chang-Claude, J.; Pantel, K.; Schwarzenbach, H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 2013, 59, 1489-1496. [CrossRef] [PubMed]
179. Wang, F.; Hou, J.; Jin,W.; Li, J.; Yue, Y.; Jin, H.;Wang, X. Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: A meta-analysis. Molecules 2014, 19, 6282-6293. [CrossRef] [PubMed]
180. Dinami, R.; Ercolani, C.; Petti, E.; Piazza, S.; Ciani, Y.; Sestito, R.; Sacconi, A.; Biagioni, F.; le Sage, C.; Agami, R.; et al. miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res. 2014, 74, 4145-4156. [CrossRef] [PubMed]
181. Asaga, S.; Kuo, C.; Nguyen, T.; Terpenning, M.; Giuliano, A.E.; Hoon, D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57, 84-91. [CrossRef] [PubMed]
182. Schwarzenbach, H.; Milde-Langosch, K.; Steinbach, B.; Muller, V.; Pantel, K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res. Treat. 2012, 134, 933-941. [CrossRef] [PubMed]
183. Wu, Q.; Lu, Z.; Li, H.; Lu, J.; Guo, L.; Ge, Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 2011. [CrossRef] [PubMed]
184. Van Schooneveld, E.;Wouters, M.C.; van der Auwera, I.; Peeters, D.J.;Wildiers, H.; van Dam, P.A.; Vergote, I.; Vermeulen, P.B.; Dirix, L.Y.; van Laere, S.J. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. BCR 2012, 14. [CrossRef] [PubMed]
185. Zhao, H.; Shen, J.; Medico, L.;Wang, D.; Ambrosone, C.B.; Liu, S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 2010, 5, e13735. [CrossRef] [PubMed]
186. Eichelser, C.; Stuckrath, I.; Muller, V.; Milde-Langosch, K.; Wikman, H.; Pantel, K.; Schwarzenbach, H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 2014, 5, 9650-9663. [CrossRef] [PubMed]
187. Jung, E.J.; Santarpia, L.; Kim, J.; Esteva, F.J.; Moretti, E.; Buzdar, A.U.; di Leo, A.; Le, X.F.; Bast, R.C., Jr.; Park, S.T.; et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118, 2603-2614. [CrossRef] [PubMed]
188. Kleivi-Sahlberg, K.; Bottai, G.; Naume, B.; Burwinkel, B.; Calin, G.A.; Borresen-Dale, A.L.; Santarpia, L. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin. Cancer Res. 2015, 21, 1207-1214. [CrossRef] [PubMed]
189. Zhao, F.L.; Hu, G.D.; Wang, X.F.; Zhang, X.H.; Zhang, Y.K.; Yu, Z.S. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J. Int. Med. Res. 2012, 40, 859-866. [CrossRef] [PubMed]
190. Madhavan, D.; Zucknick, M.; Wallwiener, M.; Cuk, K.; Modugno, C.; Scharpff, M.; Schott, S.; Heil, J.; Turchinovich, A.; Yang, R.; et al. Circulating mirnas as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18, 5972-5982. [CrossRef] [PubMed]
191. Shin, V.Y.; Siu, J.M.; Cheuk, I.; Ng, E.K.; Kwong, A. Circulating cell-free mirnas as biomarker for triple-negative breast cancer. Br. J. Cancer 2015, 112, 1751-1759. [CrossRef] [PubMed]
192. Lim, P.K.; Bliss, S.A.; Patel, S.A.; Taborga, M.; Dave, M.A.; Gregory, L.A.; Greco, S.J.; Bryan, M.; Patel, P.S.; Rameshwar, P. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011, 71, 1550-1560. [CrossRef] [PubMed]
193. Yang, M.; Chen, J.; Su, F.; Yu, B.; Lin, L.; Liu, Y.; Huang, J.D.; Song, E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 2011, 10. [CrossRef] [PubMed]
194. Chen,W.X.; Liu, X.M.; Lv, M.M.; Chen, L.; Zhao, J.H.; Zhong, S.L.; Ji, M.H.; Hu, Q.; Luo, Z.;Wu, J.Z.; et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE 2014, 9, e95240. [CrossRef] [PubMed]
195. Zhou,W.; Fong, M.Y.; Min, Y.; Somlo, G.; Liu, L.; Palomares, M.R.; Yu, Y.; Chow, A.; O'Connor, S.T.; Chin, A.R.; et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014, 25, 501-515. [CrossRef] [PubMed]
196. Pecot, C.V.; Calin, G.A.; Coleman, R.L.; Lopez-Berestein, G.; Sood, A.K. RNA interference in the clinic: Challenges and future directions. Nat. Rev. Cancer 2011, 11, 59-67. [CrossRef] [PubMed]
197. Song, E.; Lee, S.K.;Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting fas protects mice from fulminant hepatitis. Nat. Med. 2003, 9, 347-351. [CrossRef] [PubMed]
198. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with "antagomirs". Nature 2005, 438, 685-689. [CrossRef] [PubMed]
199. Nana-Sinkam, S.P.; Croce, C.M. MicroRNAs as therapeutic targets in cancer. Transl. Res. Lab. Clin. Med. 2011, 157, 216-225. [CrossRef] [PubMed]
200. Xing, Z.; Lin, A.; Li, C.; Liang, K.;Wang, S.; Liu, Y.; Park, P.K.; Qin, L.;Wei, Y.; Hawke, D.H.; et al. LncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell 2014, 159, 1110-1125. [CrossRef] [PubMed]
201. Ebert, M.S.; Neilson, J.R.; Sharp, P.A. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4, 721-726. [CrossRef] [PubMed]
202. Petrs-Silva, H.; Linden, R. Advances in recombinant adeno-associated viral vectors for gene delivery. Curr. Gene Ther. 2013, 13, 335-345. [CrossRef] [PubMed]
203. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017. [CrossRef] [PubMed]
204. Trepel, M.; Korbelin, J.; Spies, E.; Heckmann, M.B.; Hunger, A.; Fehse, B.; Katus, H.A.; Kleinschmidt, J.A.; Muller, O.J.; Michelfelder, S. Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors. Gene Ther. 2015, 22, 840-847. [CrossRef] [PubMed]
205. Gandellini, P.; Profumo, V.; Folini, M.; Zaffaroni, N. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin. Ther. Targets 2011, 15, 265-279. [CrossRef] [PubMed]
206. Muthiah, M.; Park, I.K.; Cho, C.S. Nanoparticle-mediated delivery of therapeutic genes: Focus on miRNA therapeutics. Expert Opin. Drug Deliv. 2013, 10, 1259-1273. [CrossRef] [PubMed]
207. Shu, D.; Li, H.; Shu, Y.; Xiong, G.; Carson, W.E., 3rd; Haque, F.; Xu, R.; Guo, P. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 2015, 9, 9731-9740. [CrossRef] [PubMed]
208. Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28, 1057-1068. [CrossRef] [PubMed]
209. Fraga, M.F.; Ballestar, E.; Paz, M.F.; Ropero, S.; Setien, F.; Ballestar, M.L.; Heine-Suner, D.; Cigudosa, J.C.; Urioste, M.; Benitez, J.; et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA 2005, 102, 10604-10609. [CrossRef] [PubMed]
210. Kaminsky, Z.A.; Tang, T.; Wang, S.C.; Ptak, C.; Oh, G.H.; Wong, A.H.; Feldcamp, L.A.; Virtanen, C.; Halfvarson, J.; Tysk, C.; et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat. Genet. 2009, 41, 240-245. [CrossRef] [PubMed]
211. Feinberg, A.P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301, 89-92. [CrossRef] [PubMed]
212. Altun, G.; Loring, J.F.; Laurent, L.C. DNA methylation in embryonic stem cells. J. Cell. Biochem. 2010, 109, 1-6. [CrossRef] [PubMed]
213. Straussman, R.; Nejman, D.; Roberts, D.; Steinfeld, I.; Blum, B.; Benvenisty, N.; Simon, I.; Yakhini, Z.; Cedar, H. Developmental programming of CpG island methylation profiles in the human genome. Nat. Struct. Mol. Biol. 2009, 16, 564-571. [CrossRef] [PubMed]
214. Li, E.; Bestor, T.H.; Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69, 915-926. [CrossRef]
215. Okano, M.; Bell, D.W.; Haber, D.A.; Li, E. DNA methyltransferases DNMT3A and DNMT3B are essential for de novo methylation and mammalian development. Cell 1999, 99, 247-257. [CrossRef]
216. Lopez-Serra, L.; Esteller, M. Proteins that bind methylated DNA and human cancer: Reading the wrong words. Br. J. Cancer 2008, 98, 1881-1885. [CrossRef] [PubMed]
217. Medvedeva, Y.A.; Khamis, A.M.; Kulakovskiy, I.V.; Ba-Alawi,W.; Bhuyan, M.S.; Kawaji, H.; Lassmann, T.; Harbers, M.; Forrest, A.R.; Bajic, V.B. Effects of cytosine methylation on transcription factor binding sites. BMC Genom. 2014, 15. [CrossRef] [PubMed]
218. Watt, F.; Molloy, P.L. Cytosine methylation prevents binding to DNA of a hela cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 1988, 2, 1136-1143. [CrossRef] [PubMed]
219. Doi, A.; Park, I.-H.; Wen, B.; Murakami, P.; Aryee, M.J.; Irizarry, R.; Herb, B.; Ladd-Acosta, C.; Rho, J.; Loewer, S.; et al. Differential methylation of tissue- and cancer-specific cpg island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 2009, 41, 1350-1353. [CrossRef] [PubMed]
220. Urdinguio, R.G.; Sanchez-Mut, J.V.; Esteller, M. Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol. 2009, 8, 1056-1072. [CrossRef]
221. Berman, H.; Zhang, J.; Crawford, Y.G.; Gauthier, M.L.; Fordyce, C.A.; McDermott, K.M.; Sigaroudinia, M.; Kozakiewicz, K.; Tlsty, T.D. Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 317-327. [CrossRef] [PubMed]
222. Dickinson, R.E.; Dallol, A.; Bieche, I.; Krex, D.; Morton, D.; Maher, E.R.; Latif, F. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br. J. Cancer 2004, 91, 2071-2078. [CrossRef] [PubMed]
223. Yan, P.S.; Perry, M.R.; Laux, D.E.; Asare, A.L.; Caldwell, C.W.; Huang, T.H. CpG island arrays: An application toward deciphering epigenetic signatures of breast cancer. Clin. Cancer Res. 2000, 6, 1432-1438. [PubMed]
224. Widschwendter, M.; Siegmund, K.D.; Muller, H.M.; Fiegl, H.; Marth, C.; Muller-Holzner, E.; Jones, P.A.; Laird, P.W. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004, 64, 3807-3813. [CrossRef] [PubMed]
225. Keshet, I.; Schlesinger, Y.; Farkash, S.; Rand, E.; Hecht, M.; Segal, E.; Pikarski, E.; Young, R.A.; Niveleau, A.; Cedar, H.; et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat. Genet. 2006, 38, 149-153. [CrossRef] [PubMed]
226. Ruike, Y.; Imanaka, Y.; Sato, F.; Shimizu, K.; Tsujimoto, G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genom. 2010, 11. [CrossRef] [PubMed]
227. Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.; Ngo, Q.M.; et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462, 315-322. [CrossRef] [PubMed]
228. Bibikova, M.; Barnes, B.; Tsan, C.; Ho, V.; Klotzle, B.; Le, J.M.; Delano, D.; Zhang, L.; Schroth, G.P.; Gunderson, K.L.; et al. High density DNA methylation array with single CpG site resolution. Genomics 2011, 98, 288-295. [CrossRef] [PubMed]
229. Pang, J.M.; Dobrovic, A.; Fox, S.B. DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res. BCR 2013, 15. [CrossRef] [PubMed]
230. Muggerud, A.A.; Ronneberg, J.A.; Warnberg, F.; Botling, J.; Busato, F.; Jovanovic, J.; Solvang, H.; Bukholm, I.; Borresen-Dale, A.L.; Kristensen, V.N.; et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. BCR 2010, 12. [CrossRef] [PubMed]
231. Van Hoesel, A.Q.; Sato, Y.; Elashoff, D.A.; Turner, R.R.; Giuliano, A.E.; Shamonki, J.M.; Kuppen, P.J.; van de Velde, C.J.; Hoon, D.S. Assessment of DNA methylation status in early stages of breast cancer development. Br. J. Cancer 2013, 108, 2033-2038. [CrossRef] [PubMed]
232. Fleischer, T.; Frigessi, A.; Johnson, K.C.; Edvardsen, H.; Touleimat, N.; Klajic, J.; Riis, M.L.; Haakensen, V.D.; Warnberg, F.; Naume, B.; et al. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol. 2014, 15. [CrossRef]
233. Bediaga, N.G.; Acha-Sagredo, A.; Guerra, I.; Viguri, A.; Albaina, C.; Ruiz Diaz, I.; Rezola, R.; Alberdi, M.J.; Dopazo, J.; Montaner, D.; et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. BCR 2010, 12. [CrossRef] [PubMed]
234. Holm, K.; Hegardt, C.; Staaf, J.; Vallon-Christersson, J.; Jonsson, G.; Olsson, H.; Borg, A.; Ringner, M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. BCR 2010, 12. [CrossRef] [PubMed]
235. Ronneberg, J.A.; Fleischer, T.; Solvang, H.K.; Nordgard, S.H.; Edvardsen, H.; Potapenko, I.; Nebdal, D.; Daviaud, C.; Gut, I.; Bukholm, I.; et al. Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol. Oncol. 2011, 5, 61-76. [CrossRef] [PubMed]
236. Flanagan, J.M.; Cocciardi, S.;Waddell, N.; Johnstone, C.N.; Marsh, A.; Henderson, S.; Simpson, P.; da Silva, L.; Khanna, K.; Lakhani, S.; et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet. 2010, 86, 420-433. [CrossRef] [PubMed]
237. Conway, K.; Edmiston, S.N.; May, R.; Kuan, P.F.; Chu, H.; Bryant, C.; Tse, C.K.; Swift-Scanlan, T.; Geradts, J.; Troester, M.A.; et al. DNA methylation profiling in the carolina breast cancer study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res. BCR 2014, 16. [CrossRef] [PubMed]
238. Stefansson, O.A.; Moran, S.; Gomez, A.; Sayols, S.; Arribas-Jorba, C.; Sandoval, J.; Hilmarsdottir, H.; Olafsdottir, E.; Tryggvadottir, L.; Jonasson, J.G.; et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol. Oncol. 2015, 9, 555-568. [CrossRef] [PubMed]
239. Jing, F.; Yuping,W.; Yong, C.; Jie, L.; Jun, L.; Xuanbing, T.; Lihua, H. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol. 2010, 31, 321-331. [CrossRef] [PubMed]
240. Radpour, R.; Barekati, Z.; Kohler, C.; Lv, Q.; Burki, N.; Diesch, C.; Bitzer, J.; Zheng, H.; Schmid, S.; Zhong, X.Y. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS ONE 2011, 6, e16080. [CrossRef] [PubMed]
241. Stirzaker, C.; Zotenko, E.; Song, J.Z.; Qu,W.; Nair, S.S.; Locke,W.J.; Stone, A.; Armstong, N.J.; Robinson, M.D.; Dobrovic, A.; et al. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat. Commun. 2015, 6. [CrossRef] [PubMed]
242. Veeck, J.; Ropero, S.; Setien, F.; Gonzalez-Suarez, E.; Osorio, A.; Benitez, J.; Herman, J.G.; Esteller, M. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 2010, 28, e563-e564. [CrossRef] [PubMed]
243. Stefansson, O.A.; Jonasson, J.G.; Olafsdottir, K.; Hilmarsdottir, H.; Olafsdottir, G.; Esteller, M.; Johannsson, O.T.; Eyfjord, J.E. CpG island hypermethylation of BRCA1 and loss of PRB as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011, 6, 638-649. [CrossRef] [PubMed]
244. Watanabe, Y.; Maeda, I.; Oikawa, R.;Wu,W.; Tsuchiya, K.;Miyoshi, Y.; Itoh, F.; Tsugawa, K.; Ohta, T. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes Cells 2013, 18, 1120-1130. [CrossRef] [PubMed]
245. Sharma, P.; Stecklein, S.R.; Kimler, B.F.; Sethi, G.; Petroff, B.K.; Phillips, T.A.; Tawfik, O.W.; Godwin, A.K.; Jensen, R.A. The prognostic value of promoter methylation in early stage triple negative breast cancer. J. Cancer Ther. Res. 2014, 3, 1-11. [CrossRef] [PubMed]
246. Xu, Y.; Diao, L.; Chen, Y.; Liu, Y.; Wang, C.; Ouyang, T.; Li, J.; Wang, T.; Fan, Z.; Fan, T.; et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann. Oncol. 2013, 24, 1498-1505. [CrossRef] [PubMed]
247. Ignatov, T.; Poehlmann, A.; Ignatov, A.; Schinlauer, A.; Costa, S.D.; Roessner, A.; Kalinski, T.; Bischoff, J. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic tnbc. Breast Cancer Res. Treat. 2013, 141, 205-212. [CrossRef] [PubMed]
248. Duursma, A.M.; Kedde, M.; Schrier, M.; le Sage, C.; Agami, R. miR-148 targets human DNMT3b protein coding region. RNA 2008, 14, 872-877. [CrossRef] [PubMed]
249. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C.; et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3a and 3b. Proc. Natl. Acad. Sci. USA 2007, 104, 15805-15810. [CrossRef] [PubMed]
250. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004, 14, 1902-1910. [CrossRef] [PubMed]
251. Ying, S.Y.; Lin, S.L. Intronic microRNAs. Biochem. Biophys. Res. Commun. 2005, 326, 515-520. [CrossRef] [PubMed]
252. Wee, E.J.H.; Peters, K.; Nair, S.S.; Hulf, T.; Stein, S.; Wagner, S.; Bailey, P.; Lee, S.Y.; Qu, W.J.; Brewster, B.; et al. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the hsa-miR-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 2012, 31, 4182-4195. [PubMed]
253. Lehmann, U.; Hasemeier, B.; Christgen, M.; Muller, M.; Romermann, D.; Langer, F.; Kreipe, H. Epigenetic inactivation of microRNA gene hsa-miR-9-1 in human breast cancer. J. Pathol. 2008, 214, 17-24. [CrossRef] [PubMed]
254. Lujambio, A.; Calin, G.A.; Villanueva, A.; Ropero, S.; Sanchez-Cespedes, M.; Blanco, D.; Montuenga, L.M.; Rossi, S.; Nicoloso, M.S.; Faller, W.J.; et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105, 13556-13561. [CrossRef] [PubMed]
255. Lujambio, A.; Ropero, S.; Ballestar, E.; Fraga, M.F.; Cerrato, C.; Setien, F.; Casado, S.; Suarez-Gauthier, A.; Sanchez-Cespedes, M.; Git, A.; et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67, 1424-1429. [CrossRef] [PubMed]
256. Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9, 435-443. [CrossRef] [PubMed]
257. Fabbri, M.; Calin, G.A. Epigenetics and miRNAs in human cancer. Adv. Genet. 2010, 70, 87-99. [PubMed]